申请人:Cerundolo Vincenzo
公开号:US20090239813A1
公开(公告)日:2009-09-24
There are disclosed compound of formula I, in which R
1
represents a hydrophobic moiety adapted to occupy the C′ channel of human CDId, R
2
represents a hydrophobic moiety adapted to occupy the A′ channel of human CDId, such that R
1
fills at least at least 30% of the occupied volume of the C′ channel compared to the volume occupied by the terminal nC
14
H
29
of the sphingosine chain of α-galactosylceramide when bound to human CDId and R
2
fills at least 30% of the occupied volume of the A′ channel compared to the volume occupied by the terminal nC
25
H
51
of the acyl chain of α-galactosylceramide when bound to human CDId R
3
represents hydrogen or OH, R
a
and R
b
each represent hydrogen and in addition, when R
3
represents hydrogen, R
a
and R
b
together may form a single bond, X represents or —CHA(CHOH)
n
Y or —P(═0)(0
−
)0CH
2
(CH0H)
m
Y, in which Y represents CHB
1
B
2
, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B
1
and B
2
represents H, OH or phenyl, and the other represents hydrogen or one of B
1
and B
2
represents hydroxyl and the other represents phenyl, in addition, when n represents 4, then A together with one of B
1
and B
2
together forms a single bond and the other of B
1
and B
2
represents H, OH or OSO
3
H and pharmaceutically acceptable salts thereof; the compounds of formula I are indicted for use in the treatment of a virus, microbial infection, parasite, an autoimmune disease, cancer, allergy or asthma